Localized Scleroderma with Limited Skin Involvement: What to Do When Topical and UV-Based Therapies Have Not Been Effective
Clinical scenario
This protocol applies to localized scleroderma confined to the dermis — limited skin involvement that does not extend into subcutaneous fat, fascia, muscle, joints, or bones, and without widespread skin involvement — in patients where standard first-line therapy has failed to produce sufficient improvement.
Previous treatment — failure condition triggering this step
First-line management for limited skin involvement includes topical glucocorticosteroids, topical calcipotriol, topical tacrolimus, and UV-based phototherapy options such as UVA1 phototherapy, PUVA therapy, and narrowband UVB phototherapy. When these therapies do not achieve reduction of skin sclerosis within 8 to 12 weeks — or when they are contraindicated — escalation to an alternative approach is indicated.
Next treatment approach (partial overview)
For this clinical situation, a laser-based modality is among the options recommended. The structured protocol — including specific selection criteria, clinical considerations, and sequencing — is available in full via the link below.
References
DOI: 10.1111/ddg.15328
- For cases of limited skin involvement, the guideline primarily recommends therapy with topical corticosteroids.
- In contrast, UV radiation is not suitable for types involving deeper structures such as adipose tissue, fascia, muscles, and bones.
- Pulsed dye laser (PDL) and fractional laser (CO2 laser) may be considered for the treatment of LoS in types with limited skin involvement if standard UV and topical therapies are contraindicated or have not been effective.
View source ↗